|
CA2848212C
(en)
|
2011-09-08 |
2022-03-29 |
Sage Therapeutics, Inc. |
Neuroactive steroids, compositions, and uses thereof
|
|
EP3572417B1
(en)
|
2011-10-14 |
2025-12-17 |
Sage Therapeutics, LLC |
3,3 disubstituted 19-nor pregnane compounds, compositions, and uses thereof
|
|
EP2806877B2
(en)
|
2012-01-23 |
2025-01-29 |
Sage Therapeutics, Inc. |
Neuroactive steroid formulations comprising a complex of allopregnanolone and sulfobutyl ether beta-cyclodextrin
|
|
CA2882708A1
(en)
|
2012-08-21 |
2014-02-27 |
Sage Therapeutics, Inc. |
Methods of treating epilepsy or status epilepticus
|
|
AU2013352141B2
(en)
|
2012-11-30 |
2018-04-05 |
The Regents Of The University Of California |
Anticonvulsant activity of steroids
|
|
PT2968369T
(pt)
|
2013-03-13 |
2018-12-05 |
Sage Therapeutics Inc |
Esteroides neuroativos e métodos para o seu uso
|
|
KR102396328B1
(ko)
|
2013-04-17 |
2022-05-10 |
세이지 테라퓨틱스, 인크. |
19-노르 c3,3-이치환된 c21-n-피라졸릴 스테로이드 및 그의 사용 방법
|
|
US9725481B2
(en)
|
2013-04-17 |
2017-08-08 |
Sage Therapeutics, Inc. |
19-nor C3, 3-disubstituted C21-C-bound heteroaryl steroids and methods of use thereof
|
|
EP2986624B1
(en)
|
2013-04-17 |
2020-03-25 |
Sage Therapeutics, Inc. |
19-nor neuroactive steroids for methods of treatment
|
|
US20160068563A1
(en)
|
2013-04-17 |
2016-03-10 |
Boyd L. Harrison |
19-nor neuroactive steroids and methods of use thereof
|
|
SI3021852T1
(sl)
|
2013-07-19 |
2021-07-30 |
Sage Therapeutics, Inc. |
Nevroaktivni steroidi, sestavki in uporabe le-teh
|
|
AU2014308621C1
(en)
|
2013-08-23 |
2022-01-06 |
Sage Therapeutics, Inc. |
Neuroactive steroids, compositions, and uses thereof
|
|
US10259840B2
(en)
|
2014-06-18 |
2019-04-16 |
Sage Therapeutics, Inc. |
Oxysterols and methods of use thereof
|
|
US10246482B2
(en)
|
2014-06-18 |
2019-04-02 |
Sage Therapeutics, Inc. |
Neuroactive steroids, compositions, and uses thereof
|
|
WO2016036724A1
(en)
|
2014-09-02 |
2016-03-10 |
The Texas A&M University System |
Method of treating organophosphate intoxication
|
|
JOP20200195A1
(ar)
|
2014-09-08 |
2017-06-16 |
Sage Therapeutics Inc |
سترويدات وتركيبات نشطة عصبياً، واستخداماتها
|
|
ME03809B
(me)
|
2014-10-16 |
2021-04-20 |
Sage Therapeutics Inc |
KOMPOZICIJE I POSTUPCI ZA LEČENJE POREMEĆAJA CNS-a
|
|
CN117024501A
(zh)
|
2014-10-16 |
2023-11-10 |
萨奇治疗股份有限公司 |
靶向cns障碍的组合物和方法
|
|
WO2016082789A1
(en)
|
2014-11-27 |
2016-06-02 |
Sage Therapeutics, Inc. |
Compositions and methods for treating cns disorders
|
|
RS61530B1
(sr)
|
2015-01-26 |
2021-04-29 |
Sage Therapeutics Inc |
Kompozicije i postupci za lečenje poremećaja cns
|
|
EP4155314A1
(en)
|
2015-02-20 |
2023-03-29 |
Sage Therapeutics, Inc. |
Neuroactive steroids, compositions, and uses thereof
|
|
CA2991311C
(en)
|
2015-07-06 |
2025-05-06 |
Sage Therapeutics, Inc. |
OXYSTEROLS AND THEIR METHODS OF USE
|
|
HUE071964T2
(hu)
|
2015-07-06 |
2025-10-28 |
Sage Therapeutics Inc |
Oxiszterolok és alkalmazási eljárásaik
|
|
EP3828194B1
(en)
|
2015-07-06 |
2025-04-16 |
Sage Therapeutics, Inc. |
Oxysterols and methods of use thereof
|
|
KR20240157128A
(ko)
*
|
2016-03-08 |
2024-10-31 |
세이지 테라퓨틱스, 인크. |
신경활성 스테로이드, 조성물, 및 그의 용도
|
|
SMT202200300T1
(it)
|
2016-04-01 |
2022-09-14 |
Sage Therapeutics Inc |
Ossisteroli e relativi metodi d'uso
|
|
WO2017193046A1
(en)
|
2016-05-06 |
2017-11-09 |
Sage Therapeutics, Inc. |
Oxysterols and methods of use thereof
|
|
ES2884071T3
(es)
|
2016-07-07 |
2021-12-10 |
Sage Therapeutics Inc |
24-hidroxiesteroles sustituidos en 11 para el tratamiento de afecciones relacionadas con NMDA
|
|
MA45599A
(fr)
*
|
2016-07-11 |
2019-05-15 |
Sage Therapeutics Inc |
Stéroïdes neuroactifs substitués en c17, c20 et c21 et leurs procédés d'utilisation
|
|
WO2018013615A1
(en)
|
2016-07-11 |
2018-01-18 |
Sage Therapeutics, Inc. |
C7, c12, and c16 substituted neuroactive steroids and their methods of use
|
|
EP3504189A1
(en)
|
2016-08-23 |
2019-07-03 |
Sage Therapeutics, Inc. |
A crystalline 19-nor c3, 3-disubstituted c21-n-pyrazolyl steroid
|
|
ES2935057T3
(es)
|
2016-09-30 |
2023-03-01 |
Sage Therapeutics Inc |
C7 oxisteroles sustituidos y estos compuestos para su uso como moduladores de la NMDA
|
|
RU2019115113A
(ru)
|
2016-10-18 |
2020-11-24 |
Сейдж Терапьютикс, Инк. |
Оксистеролы и способы их применения
|
|
KR20230051723A
(ko)
|
2016-10-18 |
2023-04-18 |
세이지 테라퓨틱스, 인크. |
옥시스테롤 및 그의 사용 방법
|
|
EP3750909B1
(en)
*
|
2018-02-11 |
2025-03-05 |
Jiangsu Hansoh Pharmaceutical Group Co., Ltd. |
Steroid derivative regulators, method for preparing the same, and uses thereof
|
|
WO2019154257A1
(zh)
*
|
2018-02-11 |
2019-08-15 |
江苏豪森药业集团有限公司 |
一种甾族类衍生物调节剂及其制备方法和应用
|
|
SG11202112391UA
(en)
|
2019-05-31 |
2021-12-30 |
Sage Therapeutics Inc |
Neuroactive steroids and compositions thereof
|
|
US12215126B2
(en)
*
|
2020-05-21 |
2025-02-04 |
Brigham Young University |
Cationic steroidal antimicrobial compounds with endogenous groups
|
|
WO2023060067A1
(en)
|
2021-10-04 |
2023-04-13 |
Marinus Pharmaceuticals, Inc. |
Amorphous solid dispersion ganaxolone formulation
|